Novozymes A/S – (NASDAQ:NVZMY)‘s stock had its “hold” rating restated by Jefferies Group LLC in a research note issued to investors on Tuesday, May 9th. They presently have a $47.50 price objective on the biotechnology company’s stock. Jefferies Group LLC’s target price points to a potential upside of 9.52% from the company’s current price.
Several other research analysts also recently issued reports on NVZMY. Zacks Investment Research upgraded shares of Novozymes A/S – from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a report on Thursday, February 9th. JPMorgan Chase & Co. downgraded shares of Novozymes A/S – from an “overweight” rating to a “neutral” rating in a report on Friday, February 10th. Finally, Goldman Sachs Group Inc downgraded shares of Novozymes A/S – from a “neutral” rating to a “sell” rating in a report on Wednesday, February 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the stock. Novozymes A/S – presently has an average rating of “Hold” and a consensus price target of $46.25.
Novozymes A/S – (NASDAQ:NVZMY) traded up 1.487% during trading on Tuesday, reaching $44.015. The company had a trading volume of 9,146 shares. Novozymes A/S – has a 12-month low of $31.57 and a 12-month high of $49.55. The stock has a market cap of $13.07 billion and a P/E ratio of 29.402. The firm has a 50-day moving average price of $41.92 and a 200 day moving average price of $37.90.
Novozymes A/S – (NASDAQ:NVZMY) last posted its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.01. The company had revenue of $535.97 million for the quarter. Equities research analysts predict that Novozymes A/S – will post $1.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/05/19/novozymes-as-nvzmy-stock-rating-reaffirmed-by-jefferies-group-llc-updated.html.
Novozymes A/S – Company Profile
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.
Receive News & Ratings for Novozymes A/S - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S - and related companies with MarketBeat.com's FREE daily email newsletter.